RO OFFERS ELI LILLY'S FOUNDAYO™, THE NEWEST GLP-1 INNOVATION

Foundayo™ gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo™ (orforglipron) – Eli Lilly...